Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : LastShadow's Position Trading -- Ignore unavailable to you. Want to Upgrade?

To: Susan Saline who wrote (11225)	3/24/1999 2:49:00 PM
From: kendall harmon	Respond to of 43080

SANG continues to trade in heavy volume today. Keep your eye on it. Here is a key post from the Yahoo SANG thread. I have no position yet. Company: SangStat Medical Corp.Price: 13Recommendation: STRONG BUYNotes: a, b,f Firm: Hambrecht & QuistDepartment: HealthcareIndustry: Biotechnology Date: 3/24/99 Q1 Q2 Q3 Q4 FY 1998A ($0.42)A (0.56)A (0.64)A (0.57)A (2.20)A 1999E ($0.60) (0.46) (0.32) 0.10 (1.29) 2000E --- --- --- --- 1.43 52-Week Range 13-41 Market Cap 210 Shares Out 16.2 Cash (M) $37 Cash per Share $2.28 '99 SangCya Sales $25 mil '99 Thymo Sales $34 mil FY Revs 19.5 CY EPS (2.20) ** CY P/E NM At $13, SANG Looks Like Bargain of the Year We are adding SANG to the H&Q focus list. We think our Q1 ($0.60) is conservative; we have fine-tuned our Q1 sales -- raising Thymoglobulin from $0.7 to $1.3 million and lowering SangCya liquid from $2.4 to 1.7 million. The rumor that may be responsible for today's sell-off is that Novartis has filed an ANDA for a generic. We would be not be surprised if this were true, but we doubt that Novartis would destroy its own largest product. At $13, we think SANG is the bargain of the year - trading at only 4x revenue run-rate and only 13x our $1.00 EPS estimate in 2000. (poster: lerasa)